Author

Prasad Apsangikar

Observed names: Prasad Dattatray Apsangikar, PrasadDattatray Apsangikar

Institution: Reliance Industries (India)

Observed institution: Reliance Industries (India)

ORCID: 0000-0001-7111-5380

Observed ORCID: 0000-0001-7111-5380

OpenAlex ID: A5000453363

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration

2021 · Prasad Apsangikar, Pravin Ghadge, et al. · Clinical ophthalmology · 24

Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer

2017 · PrasadDattatray Apsangikar, SunilRamdev Chaudhry, et al. · Indian Journal of Cancer · 14

Randomized Comparative Clinical Study of First Global Omalizumab Biosimilar with Innovator Product in Moderate to Severe Persistent Asthma.

2020 · Prasad Apsangikar, Pravin Ghadge, et al. · PubMed · 10

A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer

2017 · Prasad Apsangikar, Sunil Chaudhry, et al. · Indian Journal of Cancer · 10

A Prospective, Randomized, Double-blind, Comparative Clinical Study of Efficacy and Safety of a Biosimilar Adalimumab with Innovator Product in Patients with Active Rheumatoid Arthritis on a Stable Dose of Methotrexate

2018 · Prasad Apsangikar, Sunil Chaudhry, et al. · Indian Journal of Rheumatology · 6

Comparative efficacy and safety of biosimilar darbepoetin alfa in adults with anemia of chronic kidney disease

2018 · Prasad Apsangikar, Sunil Chaudhry, et al. · Indian Journal of Transplantation · 4

Multicentric, randomized, double-blind, comparative study in STEMI patients to establish clinical biosimilarity of biosimilar tenecteplase with reference product

2019 · Prasad Apsangikar, Sunil Chaudhry, et al. · Annals of Clinical Cardiology · 3

A phase III, multicentric, open-label, two-arm, parallel group, active-control, randomized, comparative clinical study to evaluate efficacy and safety of RituxiRel™ arm (rituximab) with reference arm (rituximab) in patients with non-Hodgkin's lymphoma

2017 · Prasad Apsangikar, Sunil Chaudhry, et al. · Asian Journal of Oncology · 3

A Phase-IV Multicentric Study to Evaluate Postmarketing, Real-World, Additional Safety, and Efficacy Data for TenecteRelR (Tenecteplase)

2023 · Prasad Dattatray Apsangikar, Sumeet M. Rathod, et al. · Annals of Clinical Cardiology

A prospective, multicenter, clinical Study to evaluate the Safety, Pharmacokinetics, and Efficacy of Bleed Outcomes, with HemoRel-A® in severe Hemophilia A Patients

2022 · Mayur Mewada, Subhaprakash Sanyal, et al. · Journal of the Association of Physicians of India

Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology

2022 · Prasad Apsangikar, Prashant Shirsath, et al. · Asian Journal of Oncology

Works count: 11

Citation count: 74

H-index: 5

I10-index: 4